177 related articles for article (PubMed ID: 8104540)
1. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice.
Namikawa R; Ueda R; Kyoizumi S
Blood; 1993 Oct; 82(8):2526-36. PubMed ID: 8104540
[TBL] [Abstract][Full Text] [Related]
2. Propagation of human blastic myeloid leukemias in the SCID mouse.
Sawyers CL; Gishizky ML; Quan S; Golde DW; Witte ON
Blood; 1992 Apr; 79(8):2089-98. PubMed ID: 1562735
[TBL] [Abstract][Full Text] [Related]
3. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice.
Chen BP; Galy A; Kyoizumi S; Namikawa R; Scarborough J; Webb S; Ford B; Cen DZ; Chen SC
Blood; 1994 Oct; 84(8):2497-505. PubMed ID: 7522631
[TBL] [Abstract][Full Text] [Related]
4. Human allogeneic stem cell maintenance and differentiation in a long-term multilineage SCID-hu graft.
Fraser CC; Kaneshima H; Hansteen G; Kilpatrick M; Hoffman R; Chen BP
Blood; 1995 Sep; 86(5):1680-93. PubMed ID: 7655000
[TBL] [Abstract][Full Text] [Related]
5. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias.
Cesano A; Hoxie JA; Lange B; Nowell PC; Bishop J; Santoli D
Oncogene; 1992 May; 7(5):827-36. PubMed ID: 1570153
[TBL] [Abstract][Full Text] [Related]
6. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
7. Role of C-kit receptor in the diagnosis of leukemia: a relationship between expression of C-kit receptor and that of CD33 in leukemic blasts.
Muroi K; Amemiya Y; Miura Y; Nakamura M; Suda T
Leuk Res; 1993 Aug; 17(8):725-6. PubMed ID: 7689130
[No Abstract] [Full Text] [Related]
8. Reconstitution of SCID mice with human lymphoid and myeloid cells after transplantation with human fetal bone marrow without the requirement for exogenous human cytokines.
Kollmann TR; Kim A; Zhuang X; Hachamovitch M; Goldstein H
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8032-6. PubMed ID: 7914701
[TBL] [Abstract][Full Text] [Related]
9. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
10. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
[TBL] [Abstract][Full Text] [Related]
11. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.
Sirard C; Lapidot T; Vormoor J; Cashman JD; Doedens M; Murdoch B; Jamal N; Messner H; Addey L; Minden M; Laraya P; Keating A; Eaves A; Lansdorp PM; Eaves CJ; Dick JE
Blood; 1996 Feb; 87(4):1539-48. PubMed ID: 8608245
[TBL] [Abstract][Full Text] [Related]
12. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
13. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM
Blood; 1992 May; 79(9):2229-36. PubMed ID: 1571539
[TBL] [Abstract][Full Text] [Related]
14. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model.
Rombouts WJ; Martens AC; Ploemacher RE
Leukemia; 2000 May; 14(5):889-97. PubMed ID: 10803522
[TBL] [Abstract][Full Text] [Related]
15. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model.
Zhong RK; Donnenberg AD; Shultz LD; Swerdlow SH; Lee E; Rubin J; Kozii R; Chen J; Griffin DL; Wilson J; Ball ED
Leuk Res; 1996 Jul; 20(7):581-9. PubMed ID: 8795692
[TBL] [Abstract][Full Text] [Related]
17. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
19. The pathology of murine myelogenous leukemias.
Perkins AS
Curr Top Microbiol Immunol; 1989; 149():3-21. PubMed ID: 2659281
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
